Refractory Malignant Neoplasm Active Not Recruiting Phase 1 Trials for Navitoclax (DB12340)

IndicationStatusPhase
DBCOND0074899 (Refractory Malignant Neoplasm)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02143401Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid TumorsTreatment